Stoke Therapeutics, Inc. STOK Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s free cash flow margin?
- Stoke Therapeutics, Inc. (STOK) reported free cash flow margin of 36.2% in Q1 2025.
- How has Stoke Therapeutics, Inc.'s free cash flow margin changed year-over-year?
- Stoke Therapeutics, Inc.'s free cash flow margin increased by 103.3% year-over-year, from -1,092.9% to 36.2%.
- What is the long-term trend for Stoke Therapeutics, Inc.'s free cash flow margin?
- Over 2 years (2022 to 2024), Stoke Therapeutics, Inc.'s free cash flow margin has grown at a -9.2% compound annual growth rate (CAGR), from -288.8% to -238.1%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.